HK1160604A1 - 高溫穩定的包含氧載體的藥物組合物 - Google Patents

高溫穩定的包含氧載體的藥物組合物

Info

Publication number
HK1160604A1
HK1160604A1 HK12100981.7A HK12100981A HK1160604A1 HK 1160604 A1 HK1160604 A1 HK 1160604A1 HK 12100981 A HK12100981 A HK 12100981A HK 1160604 A1 HK1160604 A1 HK 1160604A1
Authority
HK
Hong Kong
Prior art keywords
carrier
pharmaceutical composition
temperature stable
containing pharmaceutical
stable oxygen
Prior art date
Application number
HK12100981.7A
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Original Assignee
First Gain Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1160604(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/013,847 external-priority patent/US8742073B2/en
Application filed by First Gain Internat Ltd filed Critical First Gain Internat Ltd
Publication of HK1160604A1 publication Critical patent/HK1160604A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK12100981.7A 2010-05-27 2012-02-02 高溫穩定的包含氧載體的藥物組合物 HK1160604A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34876410P 2010-05-27 2010-05-27
US13/013,847 US8742073B2 (en) 2010-05-27 2011-01-26 Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US13/083,639 US7989593B1 (en) 2010-05-27 2011-04-11 Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
PCT/US2011/032594 WO2011149602A1 (en) 2010-05-27 2011-04-15 High-temperature stable oxygen-carrier-containing pharmaceutical composition

Publications (1)

Publication Number Publication Date
HK1160604A1 true HK1160604A1 (zh) 2012-08-10

Family

ID=44314337

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12100981.7A HK1160604A1 (zh) 2010-05-27 2012-02-02 高溫穩定的包含氧載體的藥物組合物
HK12106776.3A HK1166258A1 (en) 2010-05-27 2012-07-10 A method for the preparation of high temperature stable oxygen-carrier- containing pharmaceutical composition and the use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12106776.3A HK1166258A1 (en) 2010-05-27 2012-07-10 A method for the preparation of high temperature stable oxygen-carrier- containing pharmaceutical composition and the use thereof

Country Status (21)

Country Link
US (1) US7989593B1 (zh)
EP (1) EP2411025B1 (zh)
JP (1) JP5261806B2 (zh)
KR (1) KR101185437B1 (zh)
CN (2) CN103169954B (zh)
AR (1) AR081222A1 (zh)
AU (1) AU2011221433B2 (zh)
CA (1) CA2752943C (zh)
CY (1) CY1115986T1 (zh)
DK (1) DK2411025T3 (zh)
ES (1) ES2527608T3 (zh)
HK (2) HK1160604A1 (zh)
NZ (1) NZ594915A (zh)
PL (1) PL2411025T3 (zh)
PT (1) PT2411025E (zh)
RU (1) RU2475252C1 (zh)
SA (1) SA111320476B1 (zh)
SG (1) SG182237A1 (zh)
TW (1) TWI377947B (zh)
WO (1) WO2011149602A1 (zh)
ZA (1) ZA201208726B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) * 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US9066933B2 (en) 2011-09-06 2015-06-30 Billion King International Ltd. Oral delivery for hemoglobin based oxygen carriers
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
CN103251998B (zh) * 2012-11-08 2015-09-02 亿京国际有限公司 用于血红蛋白氧载体(hboc)溶液的精确输注递送系统
EP3922643A1 (en) 2013-01-07 2021-12-15 Omniox, Inc. Polymeric forms of h-nox proteins
CA2911414C (en) * 2013-05-13 2018-09-11 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
US9814759B2 (en) 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
US20180243364A1 (en) * 2015-03-17 2018-08-30 Omniox, Inc. Modulation of tumor immunity by protein-mediated 02 delivery
US9763889B2 (en) 2015-06-29 2017-09-19 Billion King International Ltd. Oral delivery system for hemoglobin based oxygen carriers
US10052290B2 (en) 2016-02-04 2018-08-21 Billion King International Ltd. Enteric-coated hemoglobin multiparticulate for oral delivery of hemoglobin based oxygen carriers
CN106421805B (zh) * 2016-09-14 2019-06-04 中国人民解放军军事医学科学院野战输血研究所 一种右旋糖酐交联血红蛋白氧载体及其制备方法与应用
WO2020080978A2 (ru) * 2018-10-19 2020-04-23 Рахимджан Ахметджанович РОЗИЕВ Cпособ получения кровезаменителя для применения в ветеринарии
JP2022546993A (ja) 2019-08-29 2022-11-10 ビリオン キング インターナショナル リミテッド チオスクシニル架橋ヘモグロビン類似体、ならびにその使用方法及び調製方法
CN113621055B (zh) * 2021-08-23 2023-05-02 山东仙普爱瑞科技股份有限公司 一种抗菌和抗病毒的猪血红蛋白β链C端片段、表达该片段的枯草芽孢杆菌、制剂以及应用
AU2022345865A1 (en) * 2021-09-17 2024-03-14 Yale University Methods, systems and compositions for restoration and preservation of intact organs in a mammal

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
FR2548671B1 (fr) 1983-07-07 1986-05-02 Merieux Inst Procede de preparation de globine a partir d'hemoglobine et globine obtenue par ce procede
US4831012A (en) 1984-03-23 1989-05-16 Baxter International Inc. Purified hemoglobin solutions and method for making same
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
USRE34271E (en) 1984-06-27 1993-06-01 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
JPH0750329B2 (ja) 1986-06-23 1995-05-31 富士写真フイルム株式会社 画像形成材料
US5955581A (en) 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
US6150506A (en) * 1989-05-10 2000-11-21 Baxter Biotech Technology Sarl Modified hemoglobin-like compounds and methods of purifying same
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5344393A (en) 1992-02-28 1994-09-06 Alliance Pharmaceutical Corp. Use of synthetic oxygen carriers to facilitate oxygen delivery
US6187744B1 (en) 1992-03-11 2001-02-13 Michael W. Rooney Methods and compositions for regulating the intravascular flow and oxygenating activity of hemoglobin in a human or animal subject
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
US5767089A (en) 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5807831A (en) 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US5840701A (en) 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995031727A1 (en) 1994-05-13 1995-11-23 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
NZ305258A (en) * 1995-03-23 2000-10-27 Biopure Corp Stable polymerised haemoglobin blood-substitute to treat or prevent hypoxia resulting from blood loss
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US6288027B1 (en) 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
US5865784A (en) 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
EP0863918A1 (en) 1995-11-30 1998-09-16 Somatogen Inc. Method for control of functionality during cross-linking of hemoglobins
AU1716697A (en) 1996-03-21 1997-10-10 Sengewald Verpackungen Gmbh Multilayered sheet, process for the production thereof and use thereof
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
RU2080865C1 (ru) * 1996-07-08 1997-06-10 Станислав Людвигович Люблинский Способ получения гемоглобина
DE69823211T2 (de) * 1997-02-06 2004-08-26 Duke University No-modifizierte Hämoglobine und Verwendung dafür
US5814601A (en) 1997-02-28 1998-09-29 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
DE69831248T2 (de) 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
CA2317603A1 (en) 1998-01-06 1999-07-15 Cerus Corporation Methods for quenching pathogen inactivators in biological materials
CA2233725A1 (en) * 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
US6894150B1 (en) 1999-10-01 2005-05-17 Ross Walden Tye Non-pyrogenic, endotoxin-free, stroma-free tetrameric hemoglobin
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US6518010B2 (en) 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
WO2002085111A1 (en) 2001-04-18 2002-10-31 Northfield Laboratories Flexible container system for storage of stabilized hemoglobin solutions
JP4260417B2 (ja) 2001-05-23 2009-04-30 ノバルティス アクチエンゲゼルシャフト 溶液を輸送し脱酸素するためのシステム及び方法
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US20050164915A1 (en) 2002-04-01 2005-07-28 Sangart, Inc. Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US7501499B2 (en) 2002-12-23 2009-03-10 Albert Einstein College Of Medicine Of Yeshiva University Modified hemoglobin and methods of making same
BRPI0407106A (pt) 2003-01-29 2006-01-24 Northfield Lab Soluções de hemoglobina polimerizadas com quantidade reduzida de tetrâmero e método para preparação
US7135554B1 (en) * 2004-01-27 2006-11-14 Biopure Corporation Method of forming a polymerized hemoglobin solution from stabilized hemoglobin
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
WO2007065265A1 (en) 2005-12-08 2007-06-14 Ronald Kluger Cross-linking reagents for hemoglobin and hemoglobin products cross-linked therewith
US7759306B2 (en) 2006-05-16 2010-07-20 Simoni Jan S Methods of treating acute blood loss
US7795401B2 (en) 2006-09-06 2010-09-14 National Chung Cheng University Modified hemoglobin with allosteric effector conjugated
CN101168565A (zh) * 2006-10-23 2008-04-30 爱科有限公司 一氧化氮阻断的交联四聚体血红蛋白
US7494974B2 (en) 2006-10-24 2009-02-24 Ikor, Inc. Carboxymethylated cross-linked tetrameric hemoglobin
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition

Also Published As

Publication number Publication date
KR20110138215A (ko) 2011-12-26
US7989593B1 (en) 2011-08-02
AU2011221433B2 (en) 2012-03-29
PT2411025E (pt) 2015-02-04
CA2752943C (en) 2013-10-08
HK1166258A1 (en) 2012-10-26
EP2411025A1 (en) 2012-02-01
TW201141493A (en) 2011-12-01
JP2012526859A (ja) 2012-11-01
WO2011149602A1 (en) 2011-12-01
ES2527608T3 (es) 2015-01-27
RU2475252C1 (ru) 2013-02-20
DK2411025T3 (en) 2015-02-16
KR101185437B1 (ko) 2012-10-02
CN103169954A (zh) 2013-06-26
EP2411025B1 (en) 2014-11-05
SG182237A1 (en) 2012-08-30
CN102405051A (zh) 2012-04-04
CY1115986T1 (el) 2017-01-25
PL2411025T3 (pl) 2015-04-30
AU2011221433A1 (en) 2011-12-15
NZ594915A (en) 2013-06-28
WO2011149602A8 (en) 2012-05-24
SA111320476B1 (ar) 2013-07-28
CN102405051B (zh) 2013-01-23
CA2752943A1 (en) 2011-11-27
AR081222A1 (es) 2012-07-04
EP2411025A4 (en) 2012-11-14
ZA201208726B (en) 2013-09-25
TWI377947B (en) 2012-12-01
CN103169954B (zh) 2016-01-20
JP5261806B2 (ja) 2013-08-14

Similar Documents

Publication Publication Date Title
HK1246170A1 (zh) 藥物組合物
ZA201208726B (en) High-temperature stable oxygen-carrier-containing pharmaceutical composition
IL225457A0 (en) Pharmaceutical composition
RS55566B1 (sr) Farmaceutska kompozicija
EP2616076A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA201304189B (en) Novel pharmaceutical composition
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
ZA201207375B (en) Stabilized pharmaceutical composition
EP2635307A4 (en) PHARMACEUTICAL COMPOSITIONS
IL221501A (en) Medicinal product containing miramistine
GB201001911D0 (en) Pharmaceutical composition
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
GB201019775D0 (en) Pharmaceutical composition
IL226378A0 (en) preparations@rokkhot
HU1000006D0 (en) Improved pharmaceutical composition